Through Flux and Fluidity, FDA Keeps Coming Back to Rare Disease: 2026 Policy Shifts and Approvals in Rare Disease Space
The article "Through flux and fluidity, FDA keeps coming back to rare disease" highlights how, despite leadership turmoil and falling biologic approvals in the first half of 2026, the FDA is refocusing on rare disease innovation.
In H1 2026, the FDA approved six orphan drugs, including two via the Center for Biologics Evaluation and Research (CBER) and four via the Center for Drug Evaluation and Research (CDER), compared with higher totals in prior years.
Recent regulatory changes include the "plausible mechanism" pathway and the Rare Disease Evidence Principles (RDEP) framework under PDUFA VII, which aim to streamline approvals for ultra‑rare and individualized therapies where randomized trials are not feasible.
These initiatives, alongside the Rare Disease Innovation Hub and new gene‑therapy guidance, signal a more structured yet flexible approach—codifying one‑off precedents into repeatable evidence and trial‑design frameworks while maintaining scientific rigor.
Nevertheless, patient advocates and industry voices describe ongoing tension between science and politics, with some viewing recent policies as "all wrapper, no gift" while others see a clearer, more favorable path for rare disease drugs.
Sources:
Through flux and fluidity, FDA keeps coming back to rare disease
How the FDA Is Shaping the Future of Rare Disease Regulation
The FDA creates a quicker path for gene therapies
Rare disease advocates fume over FDA's mixed signals - STAT News
FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad
'All Wrapper, No Gift': FDA Releases New Rare Disease Approval ...
FDA's New Framework Signals Turning Point for Rare Disease ...
FDA Launches Framework for Accelerating Development of ...
FDA needs to build in more flexibility for rare disease trials | STAT
By loosening standards, the FDA isn't doing rare-disease patients any favors
FDA Unveils New Path for Approving Rare Disease Drugs for Just One Person
Lessons Learned from our Roundtable with Rare Disease Advocates
FDA watchers warn of agency in 'chaos' and risk to America's health
Makary touts FDA speed, flexibility for rare disease drugs - RAPS
FDA says it wants individualized medicines. Can we get there?